Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Abbott Laboratories (ABT) Stock Price & Analysis

2 Followers

ABT Stock Chart & Stats

CHF 91.00CHF 0.50(0.55%)
At close: 5:30 PM GMT+1
CHF73CHF74Jun 8Jun 10Jun 12
Day’s Range
CHF 91.00 - CHF 92.00
52-Week Range
CHF 63.50 - CHF 108.00
Previous Close
CHF 90.50
Volume
N/A
Average Volume (3M)
0
Market Cap
CHF 159.22B
Enterprise Value
CHF 199.21B
Total Cash (Recent Filing)
CHF 4.30B
Total Debt (Recent Filing)
CHF 31.16B
Price to Earnings (P/E)
40.5
Beta
0.12
Next Earnings
Jan 27, 2027 (Est.)
EPS Estimate
1.34
Last Dividend Ex-Date
Oct 15, 2026
Dividend Yield
2.47%

Bulls Say, Bears Say

Bulls Say

Diversified Healthcare Platform

Abbott’s presence across four healthcare categories diversifies revenue sources and reduces dependence on any single product cycle. Diagnostics and diabetes consumables also create recurring demand, while devices, nutrition, and pharmaceuticals provide additional channels for geographic and product expansion.

Growth With Margin Expansion

Recent acceleration in sales and earnings, together with wider gross and operating margins, indicates operating leverage and effective execution. If sustained, this combination can strengthen internal funding for innovation while improving the earnings contribution from Abbott’s expanding healthcare portfolio.

Innovation Pipeline

Abbott is committing substantial resources to a broad pipeline spanning cardiovascular devices, diabetes monitoring, diagnostics, and pharmaceuticals. Continued investment supports product renewal, expands addressable markets, and can reinforce competitive advantages as healthcare technology adoption increases.

Bears Say

Higher Leverage And Softer Cash Flow

The sharp increase in debt reduces financial flexibility and raises sensitivity to interest costs, even though equity remains sizeable. At the same time, declining free cash flow weakens internally generated funding, potentially constraining acquisitions, investment, or shareholder returns if softness persists.

Diabetes Growth And Pricing Pressure

Moderating diabetes growth affects an important technology-driven business and reflects difficulty expanding among type 2 patients without broader reimbursement. International pricing pressure may further reduce revenue quality, making near-term growth and margin improvement more dependent on other segments.

Ongoing NEC Litigation Exposure

Although Abbott has settled claims involving approximately 2,000 claimants, the remaining litigation creates continuing financial and management uncertainty. Potential liabilities and defense costs could absorb capital, complicate the nutrition separation, and distract from operating priorities over the coming quarters.

Abbott Laboratories News

ABT FAQ

What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was CHF63.50 and its highest was CHF108.00 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is CHF159.22B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s next earnings report is estimated for Jan 27, 2027 (not yet confirmed), which is in 76 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 21, 2026. The company reported CHF1.165 earnings per share for the quarter.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a quarterly dividend of CHF0.519 which represents an annual dividend yield of 2.47%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.34.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,731,941,700 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of CHF1.165 in its last earnings report. Following the earnings report the stock price went down -4.678%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Hedge funds hold Abbott Laboratories shares: the largest hedge-fund position in Abbott Laboratories is 1,916,098,334 shares, and hedge funds decreased their holdings by 1.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology